134 related articles for article (PubMed ID: 11221133)
1. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide.
Coggins C; Blanchard K; Alvarez F; Brache V; Weisberg E; Kilmarx PH; Lacarra M; Massai R; Mishell D; Salvatierra A; Witwatwongwana P; Elias C; Ellertson C
Sex Transm Infect; 2000 Dec; 76(6):480-3. PubMed ID: 11221133
[TBL] [Abstract][Full Text] [Related]
2. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
Jones HE; Chaikummao S; van de Wijgert JH; Friedland BA; Manopaiboon C; Witwatwongwana P; Wankrairot M; Chantharojwong N; Kilmarx PH
J Womens Health (Larchmt); 2009 Jul; 18(7):1003-10. PubMed ID: 19575689
[TBL] [Abstract][Full Text] [Related]
3. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.
Elias CJ; Coggins C; Alvarez F; Brache V; Fraser IS; Lacarra M; Lähteenmäki P; Massai R; Mishell DR; Phillips DM; Salvatierra AM
Contraception; 1997 Dec; 56(6):387-9. PubMed ID: 9494773
[TBL] [Abstract][Full Text] [Related]
4. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.
Doh AS; Ngoh N; Roddy R; Lai JJ; Linton K; Mauck C
Contraception; 2007 Sep; 76(3):245-9. PubMed ID: 17707724
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
[TBL] [Abstract][Full Text] [Related]
6. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa.
Carraguard Phase II South Africa Study Team
Contraception; 2010 Dec; 82(6):563-71. PubMed ID: 21074021
[TBL] [Abstract][Full Text] [Related]
7. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
Bakobaki JM; Lacey CJ; Bukenya MI; Nunn AJ; McCormack S; Byaruhanga RN; Okong P; Namukwaya SW; Grosskurth H; Whitworth JA
AIDS; 2005 Dec; 19(18):2149-56. PubMed ID: 16284465
[TBL] [Abstract][Full Text] [Related]
10. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
12. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
[No Abstract] [Full Text] [Related]
13. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Malonza IM; Mirembe F; Nakabiito C; Odusoga LO; Osinupebi OA; Hazari K; Chitlange S; Ali MM; Callahan M; Van Damme L
AIDS; 2005 Dec; 19(18):2157-63. PubMed ID: 16284466
[TBL] [Abstract][Full Text] [Related]
14. Acceptability of Carraguard vaginal gel use among Thai couples.
Whitehead SJ; Kilmarx PH; Blanchard K; Manopaiboon C; Chaikummao S; Friedland B; Achalapong J; Wankrairoj M; Mock P; Thanprasertsuk S; Tappero JW
AIDS; 2006 Nov; 20(17):2141-8. PubMed ID: 17086053
[TBL] [Abstract][Full Text] [Related]
15. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.
Kamali A; Byomire H; Muwonge C; Bakobaki J; Rutterford C; Okong P; Profy A; Byaruhanga R; Namukwaya S; McCormack S; Grosskurth H; Nunn AJ; Lacey CJ
Sex Transm Infect; 2010 Jun; 86(3):222-6. PubMed ID: 20444744
[TBL] [Abstract][Full Text] [Related]
16. Carraguard acceptability among men and women in a couples study in Thailand.
Martin S; Blanchard K; Manopaiboon C; Chaikummao S; Schaffer K; Friedland B; Kilmarx PH
J Womens Health (Larchmt); 2010 Aug; 19(8):1561-7. PubMed ID: 20575712
[TBL] [Abstract][Full Text] [Related]
17. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
[TBL] [Abstract][Full Text] [Related]
18. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
Giguere R; Carballo-Diéguez A; Ventuneac A; Mabragaña M; Dolezal C; Chen BA; Kahn JA; Zimet GD; McGowan I
Cult Health Sex; 2012; 14(2):151-66. PubMed ID: 22084840
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners.
Trottier S; Omar RF; Désormeaux A; Drouin J; Gagnon MT; Vezina F; Guilbert E; Mâsse B; Bergeron MG
Contraception; 2007 Aug; 76(2):117-25. PubMed ID: 17656181
[TBL] [Abstract][Full Text] [Related]
20. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
